Study on the Prevalence of Human Papillomavirus Types in Women >= 15 Years of Age in the Kingdom of Saudi Arabia
An Observational, Epidemiological Study on the Prevalence of Human Papillomavirus (HPV) Types in Women >= 15 Years of Age, in the Kingdom of Saudi Arabia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Riyadh, Saudi Arabia
- GSK Investigational Site
-
Riyadh, Saudi Arabia, 11211
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects/Subjects' parents or guardians, who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study,
- Women >=15 years of age attending a clinic for routine cervical screening,
- Written informed consent obtained from the subject and/or subject's parent/guardian.
Exclusion Criteria:
- Referral for abnormal cervical sample at the current visit,
- Abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed,
- No cervical sample provided,
- History of hysterectomy,
- Known diagnosis of immunosuppression, or patient on immunosuppressives,
- Pregnant female >=25 years of age.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Cohort A
Women ≥15 years of age attending out-patient departments for routine cervical screening in the Kingdom of Saudi Arabia.
|
Questionnaire completion
Human papillomavirus detection and typing in cervical samples.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prevalence of any human papillomavirus deoxyribo nucleic acid and of different types of human papillomavirus (including multiple infections) among women undergoing cervical screening.
Time Frame: At least 12 months from the date of subject enrolment
|
At least 12 months from the date of subject enrolment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prevalence of any human papillomavirus deoxyribo nucleic acid and of different types of human papillomavirus (high risk and low risk) among women of different age strata undergoing cervical screening.
Time Frame: At least 12 months from the date of subject enrolment
|
At least 12 months from the date of subject enrolment
|
|
Behavioural risk factors such as age at first marriage and age at first pregnancy (assessed through administration of a behavioural questionnaire).
Time Frame: At least 12 months from the date of subject enrolment
|
At least 12 months from the date of subject enrolment
|
|
Level of awareness of human papillomavirus and its relation to transmission and to causation of cervical cancer.
Time Frame: At least 12 months from the date of subject enrolment
|
At least 12 months from the date of subject enrolment
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 111336
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.